SPDE Speedus Corp (CE)

Zargis Conducts Physician Study to Show Potential Benefits to Physicians, Insurance Companies and Patients PRINCETON, N.J., June 30 /PRNewswire/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research, and a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), today announced that it conducted a study in participation with Johns Hopkins University's School of Medicine to assess the impact of the Zargis Acoustic Cardioscan(TM) (ZAC(TM)) system on referral decisions made by primary care physicians regarding heart murmurs -- which are potential signs of heart disease. In addition, the study was designed to assess ZAC's ability to support physicians in the detection of murmurs. This study was based on the analysis, by a group of primary care physicians, of a series of heart sound recordings obtained from anonymous subjects who were referred to Johns Hopkins Hospital for a cardiology consult. The results of the study are expected to be available later this year. About Zargis Medical Corp. Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds. About ZAC Zargis has developed ZAC, the first and only FDA-authorized computer- assisted medical device to support physicians in analyzing heart sounds for the identification of suspected murmurs. The non-invasive device is easy to use, portable, and takes just minutes to perform. ZAC implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. The system provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. As a result, ZAC enhances auscultation -- a procedure that has been universally employed through a stethoscope for nearly two hundred years. About Speedus Corp. Speedus Corp. is a holding company with controlling interests in Zargis Medical Corp. and F&B Gudtfood Holdings, Inc. Speedus Corp. also owns broadband intellectual property and controls licensed wireless frequencies. For additional information about Zargis Medical, Speedus Corp. or the ZAC product, contact Peter Hodge at 888.773.3669 (ext. 23) or , or visit the following Web sites: http://www.zargis.com/ and http://www.speedus.com/. Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. DATASOURCE: Zargis Medical Corp. CONTACT: Peter Hodge, 1-888-773-3669, ext. 23, , for Zargis Medical Corp. Web site: http://www.zargis.com/ http://www.speedus.com/

Copyright